Demographic and clinical characteristics
| Total patient group | Patient survival≤2.5 years | Patient survival>2.5 years | Difference | |
| N | 17 | 9 | 8 | |
| Sex (F/M) | 7/10 | 4/5 | 3/5 | χ2=0.08, p=0.772 |
| Age (mean±SD) | 68.3±5.7 | 68.6±7.1 | 68.0±4.1 | t(15)=0.20, p=0.848 |
| Education (mean±SD) | 12.1±1.9 | 11.8±1.8 | 12.5±2.1 | t(15)=−0.77, p=0.452 |
| Symptom duration (mean±SD) | 4.7±1.5 | 4.6±1.7 | 4.8±1.5 | t(15)=−0.28, p=0.786 |
| PSPRS baseline (mean±SD) | 41.2±14.5 | 45.1±14.8 | 37.0±13.7 | t(15)=1.19, p=0.255 |
| Clinical progression following baseline–PSPRS points/year (mean±SD) | 6.2±1.5 | 6.4±0.7 | 5.9±2.1 | t(15)=0.75, p=0.468 |
Statistics are reported for the total patient group and for subgroups based on median split of survival from baseline research assessment to death (median=2.5 years, mean±SD=2.2±1.0).
PSPRS, Progressive Supranuclear Palsy Rating Scale; t(), t-test.